- Mesothelioma | Mesothelioma news are updated once a hour
- We deliver news from more than 500 sources on lung cancer
NewsAdvertisers: |
GPs urged to spend time counselling smokers... A chat with a doctor or a nurse is also the only cost-effective way of getting people to be more active, Nice said. Issuing its first public health guidance, Nice said there was a belief among health professionals that trying to persuade people to stop smoking or take more exercise was useless. "Now we can reassure them they are not wasting their breath," said Dagmar Zeuner, the director of public health for Islington Primary Care Trust, north London, and a member of the advisory panel. She compared the power of a chat with the GP to the discovery of a new drug to stop smoking. "This should be part of the core business of GPs, and smokers have a right to get it." Stopping smoking is difficult for individual smokers but the benefits to health are so great that even if only two in 100 smokers who receive a six-minute chat go on to give up, the 10 hours of effort by the GP is cost-effective, Nice calculated. Also in this section Power of the mind 'can boost muscle strength' Dentists 'may leave NHS' over contracts iPods get volume limiters after noise concerns Desperate couples 'fail to conside... Cannabis, pneumothorax and lung bullae...
JRSM - Sign In Page
HOME
HELP
FEEDBACK
SUBSCRIPTIONS
ARCHIVE
SEARCH
This item requires a subscription to Journal of the Royal Society of Medicine Online. Full Text Cannabis, pneumothorax and lung bullae: Author's reply Treasure and Tan J R Soc Med.2006; 99: 170 To view this item, select one of the options below: RSM Member Sign In RSM Members/Fellows, please sign in at the RSM to access the journal online. Non-Member Sign In User Name Sign in without cookies. Can't get past this page? Help with Cookies. Need to Activate? Password Remember my user name & password. Forgot your user name or password? Purchase Short-Term Access Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$15.00. Pay for Admission - You may access all content in Journal of the Royal Society of Medicine Online (from the computer you are currently using) for 7 days for US$25.00. Regain Access - You can regain access to a recent Pay per Article or Pay for Admission purchase if your access period has not yet expired. Sign Up Become a Member - Join the Royal Society of Medicine. Subscribe to the Journal - Subscribe to the print and/or online journal. This Article Full Text (PDF) Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Treasure, T. Articles by Tan, C. PubMed Articles by Treasure, T. Articles by Tan, C. HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH Copyright... Cytokinetics Cancer Drug Trial Fails... Cytokinetics has already abandoned part of the study last September, because the drug, Ispinesib, did not demonstrate sufficient anti-tumor activity in patients with platinum-refractory cancer. The company then said it was continuing the part of the study that focused on platinum-sensitive cancer. GlaxoSmithKline is also conducting two Phase II trials, one to evaluate the drug as a second or third-line treatment for people with an advanced form of breast cancer, and one as a second-line treatment for advanced ovarian cancer. Shares of Cytokinetics fell 44 cents, or 6.1 percent, to $6.75 in after-hours trading, having earlier closed at $7.19 on the Nasdaq. The stock has traded between $4.61 and $9.75 over the past year. Subscribe to the paper for less than thirty cents a day! Copyright Notice & Privacy Policy Place an ad ... 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news Global business blog, Economy, Human sexuality advice, Settlement funding, Taxes news blog, Cerebral problematics news, Marketing advances, Start-up news and ideas blog, Science news blog, Genetics journal, Recreation journal |